Matches in SemOpenAlex for { <https://semopenalex.org/work/W2889795857> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- W2889795857 abstract "e20607 Background: The PD-1 inhibitors nivolumab and pembrolizumab are approved for the treatment of advanced non-small cell lung cancer (NSCLC), but little is known about patterns of disease progression when these agents fail. Understanding patterns of failure is key to developing strategies to improve duration of response to these agents. Methods: We gathered clinical and radiographic data on patients treated at the University of Michigan and the Ann Arbor VA for advanced NSCLC with standard-dose nivolumab (n = 68) or pembrolizumab (n = 23) after progression on platinum-based chemotherapy. Sites of disease progression were described as local (within the same lobe as primary disease), nodal (thoracic), or distant. Results: 91 patients were evaluable, of whom 56 (61.5%) had progression of disease after an average duration of therapy of 3.2 months (95%CI, 2.6-3.8). 10 (17.9%) patients had progression at local sites alone, 3 (5.4%) at nodal sites alone, 12 (21.4%) at distant sites alone, and 31 (55.4%) at a combination of sites. Overall, 41 (73.2%) had progression at distant sites. There was no statistically significant difference in clinical factors ( i.e. age, histology, comorbidity index) between progressors vs. non-progressors or distant-progressors vs. non-distant progressors. Of 37 patients who had prior radiation, 17 (45.9%) had progression at an irradiated site, with patients who had local and/or nodal progression more likely to have received radiation at site of progression (p = 0.01). The most common distant sites of progression were liver (13), bone (10), and brain (9). Conclusions: The most common site of disease progression was distant, with the liver being the most commonly involved site. This may be due to the immunotolerogenic environment of the liver, which is characterized by high IL-10 concentration and propagation of suppressive regulatory T cells, which can dampen activation of cytotoxic T cells. Prior irradiation did not seem to prevent disease progression. Our preliminary analysis suggests that the efficacy of checkpoint inhibitors is hindered in immune-privileged sites. Strategies to overcome immune tolerance should be investigated to improve duration of response to these agents." @default.
- W2889795857 created "2018-09-27" @default.
- W2889795857 creator A5021394498 @default.
- W2889795857 creator A5028299369 @default.
- W2889795857 creator A5035074844 @default.
- W2889795857 creator A5056827435 @default.
- W2889795857 creator A5064080252 @default.
- W2889795857 creator A5066306817 @default.
- W2889795857 creator A5086113297 @default.
- W2889795857 creator A5087704838 @default.
- W2889795857 date "2017-05-20" @default.
- W2889795857 modified "2023-10-12" @default.
- W2889795857 title "Patterns of disease progression in advanced non-small cell lung cancer patients treated with PD-1 inhibitors." @default.
- W2889795857 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e20607" @default.
- W2889795857 hasPublicationYear "2017" @default.
- W2889795857 type Work @default.
- W2889795857 sameAs 2889795857 @default.
- W2889795857 citedByCount "0" @default.
- W2889795857 crossrefType "journal-article" @default.
- W2889795857 hasAuthorship W2889795857A5021394498 @default.
- W2889795857 hasAuthorship W2889795857A5028299369 @default.
- W2889795857 hasAuthorship W2889795857A5035074844 @default.
- W2889795857 hasAuthorship W2889795857A5056827435 @default.
- W2889795857 hasAuthorship W2889795857A5064080252 @default.
- W2889795857 hasAuthorship W2889795857A5066306817 @default.
- W2889795857 hasAuthorship W2889795857A5086113297 @default.
- W2889795857 hasAuthorship W2889795857A5087704838 @default.
- W2889795857 hasConcept C121608353 @default.
- W2889795857 hasConcept C126322002 @default.
- W2889795857 hasConcept C142724271 @default.
- W2889795857 hasConcept C143998085 @default.
- W2889795857 hasConcept C2776256026 @default.
- W2889795857 hasConcept C2779134260 @default.
- W2889795857 hasConcept C502942594 @default.
- W2889795857 hasConcept C71924100 @default.
- W2889795857 hasConceptScore W2889795857C121608353 @default.
- W2889795857 hasConceptScore W2889795857C126322002 @default.
- W2889795857 hasConceptScore W2889795857C142724271 @default.
- W2889795857 hasConceptScore W2889795857C143998085 @default.
- W2889795857 hasConceptScore W2889795857C2776256026 @default.
- W2889795857 hasConceptScore W2889795857C2779134260 @default.
- W2889795857 hasConceptScore W2889795857C502942594 @default.
- W2889795857 hasConceptScore W2889795857C71924100 @default.
- W2889795857 hasLocation W28897958571 @default.
- W2889795857 hasOpenAccess W2889795857 @default.
- W2889795857 hasPrimaryLocation W28897958571 @default.
- W2889795857 isParatext "false" @default.
- W2889795857 isRetracted "false" @default.
- W2889795857 magId "2889795857" @default.
- W2889795857 workType "article" @default.